Eflornithine is a topical medication used in women's health and skin-care to reduce unwanted facial hair growth. It is available as a 13.9 % gel in a single-use tube. In Hong Kong, eflornithine is classified as a prescription-only product and is regulated by the Hong Kong Department of Health. The active ingredient is eflornithine itself; no additional brand names are required for this discussion.
Eflornithine inhibits the enzyme ornithine decarboxylase, a key step in the polyamine synthesis pathway that is essential for hair follicle cell proliferation. By reducing polyamine levels, the drug slows the rate of hair shaft formation, leading to less visible hair growth over time. The gel is applied locally, so systemic absorption is minimal and the effect is confined to the treated skin area. Onset of visible reduction typically appears after several weeks of consistent use, with maximum benefit observed after several months of continued application.
Eflornithine is FDA-approved (and similarly approved by the European Medicines Agency) for the temporary reduction of unwanted facial hair in adult women. In Hong Kong, it is prescribed for the same indication. The medication is intended for use on the chin, upper lip, and cheeks. It does not permanently remove hair; instead, it slows new hair growth, allowing existing hair to be trimmed or shaved with less frequent regrowth.
Patients should always inform their healthcare provider of all medications, supplements, and cosmetic products they are using before starting eflornithine.
Routine laboratory monitoring is not required for eflornithine because it acts locally. Patients should schedule a follow-up visit with their dermatologist or primary care provider within 2-3 months of initiating therapy to assess effectiveness and skin tolerance.
This article provides educational information about eflornithine and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
The gel is formulated and approved for facial use only. Applying it to other areas may increase the risk of irritation and has not been studied for safety or efficacy.
Visible reduction typically begins after 4-6 weeks of twice-daily application, with maximum benefit observed after 3-6 months of consistent use.
No. Eflornithine slows the rate of new hair growth but does not permanently destroy hair follicles. Hair will regrow after discontinuation of the product.
Yes, many clinicians recommend using eflornithine to manage hair growth between laser sessions. However, avoid applying both treatments on the same day to reduce skin irritation.
Discontinue the gel immediately and contact a healthcare professional. A mild rash may resolve on its own, but severe or spreading reactions require medical evaluation.
Allow the gel to fully absorb (approximately 5-10 minutes) before applying makeup to minimize dilution and potential irritation.
No systemic hormonal changes have been reported because the medication acts locally on the skin with minimal absorption.
Safety data in pregnancy are limited. Use only if the potential benefit outweighs any possible risk, and discuss the decision with your obstetrician.
Keep the tube in a cool, dry place inside your luggage, avoiding direct heat (e.g., near windows or in an overheated car). Do not place it in checked baggage if temperatures may exceed room temperature.
Eflornithine is a prescription product; pricing varies by pharmacy. Some clinics may offer bulk-purchase programs, but patients should consult their healthcare provider or pharmacist for specific information.
